End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET

Haematologica. 2023 Jun 1;108(6):1697-1701. doi: 10.3324/haematol.2022.282115.

Authors

Affiliations

¹ Department of Medicine, Mayo Clinic, Rochester, MN.
² Department of Radiology, Mayo Clinic, Jacksonville, FL.
³ Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
⁴ Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
⁵ Division of Hematology, Mayo Clinic, Phoenix, AZ.
⁶ Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL.
⁷ Division of Hematology, Mayo Clinic, Rochester, MN.
⁸ Division of Hematology, Mayo Clinic, Rochester, MN. ansell.stephen@mayo.edu.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Doxorubicin / therapeutic use
Fluorodeoxyglucose F18 / therapeutic use
Hodgkin Disease* / diagnostic imaging
Hodgkin Disease* / drug therapy
Humans
Positron-Emission Tomography

Substances

Doxorubicin
Fluorodeoxyglucose F18